Henriette Burghoorn is an experienced Associate Director of Market Access at Gilead Sciences, with a strong track record in the biotechnology industry. She has extensive expertise in reimbursement strategies across a broad range of therapeutic areas, including liver disease, HIV, oncology, hematology, cardiovascular, and diabetes indications. Henriette is known for her strategic insight and dedication to improving patient access to innovative treatments.

At Gilead, we strive to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we deliver innovative therapies that offer new hope to those impacted by disease. With more than 18,000 employees, we invest in world-class science and are pursuing innovation across our therapeutic areas of virology, oncology and inflammation.